Company Of The Day: Johnson & Johnson
What?
Johnson & Johnson (NYSE:J&J) plans to split into two publically traded companies. The first company will hold the company’s prescription-drug and medical-device businesses. The second will hold the company’s consumer businesses.
So What?
Relevant Articles
- What’s Next For Johnson & Johnson Stock After Beating Q1 Earnings?
- Here’s What To Expect From Johnson & Johnson’s Q1
- What’s Next For Johnson & Johnson Stock After A 6% Decline In A Month?
- Is Johnson & Johnson Stock A Better Pick Over AbbVie?
- Will Johnson & Johnson Stock Rebound To Its Pre-Inflation Shock Highs of $185?
- Should You Pick Johnson & Johnson Stock At $160?
While J&J’s consumer business is very high profile, it lags the pharma business in terms of growth and profitability. With the planned split, J&J could potentially unlock some value for shareholders.
See Our Complete Analysis For Johnson & Johnson
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since 2016.
Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates